| Name | Title | Contact Details |
|---|
At bluebird bio, we`re pioneering the uniquely promising world of gene therapy with a deep sense of purpose – to ensure lives are lived fully. To do it, we`re developing one-time gene therapies for severe genetic disease and cancer, while working to radically improve healthcare systems so gene therapy becomes truly accessible. We want to recode science, systems and the status quo – for life. We pride ourselves on having a unique culture that drives our success. A diverse flock of individual birds, we share common DNA that helps us build meaningful relationships with industry, patient & advocacy groups and our customers. We fly as one and invite others to join us. We`re headquartered in Cambridge, MA with additional nests in Seattle, WA, Durham, NC, and Zug, Switzerland.
YmAbs has a powerful set of capabilities for the development of biologics. Our product development team includes some of the most talented and experienced professionals in the antibody industry.
Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function.
Receptor Life Sciences, Inc. develops inhaled therapeutic products for conditions including chronic pain, neurologic diseases, and inflammatory disorders.
NeuroVista Corporation is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.